

Conformational dynamics of the HIV-1 envelope glycoprotein from CRF01_AE is associated with susceptibility to antibody-dependent cellular cytotoxicity

Marco A. Díaz-Salinas¹, Debashree Chatterjee², Manon Nayrac^{2,3}, Halima Medjahed², Jérémie Prévost^{2,3}, Marzena Pazgier⁴, Andrés Finzi^{2,3,*}, James B. Munro^{1,5,*}

¹Department of Microbiology, University of Massachusetts Chan Medical School, Worcester, MA, USA.

²Centre de Recherche du CHUM, Montréal, Québec, Canada.

³Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, Québec, Canada.

⁴Infectious Diseases Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

⁵Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA, USA.

*Corresponding author: james.munro@umassmed.edu (J.B.M.), andres.finzi@umontreal.ca (A.F.)

Running title: HIV-1 CRF01_AE Env flexibility confers ADCC sensitivity.

ABSTRACT

The HIV-1 envelope glycoprotein (Env) is expressed at the surface of infected cells and as such can be targeted by non-neutralizing antibodies (nnAbs) that mediate antibody-dependent cellular cytotoxicity (ADCC). Previous single-molecule Förster resonance energy transfer (smFRET) studies demonstrated that Env from clinical isolates predominantly adopt a “closed” conformation (State 1), which is resistant to nnAbs. After interacting with the cellular receptor CD4, the conformational equilibrium of Env shifts toward States 2 and 3, exposing the coreceptor binding site (CoRBS) and permitting binding of antibodies targeting this site. We showed that the binding of anti-CoRBS Abs enables the engagement of other nnAbs that target the cluster A epitopes on Env. Anti-cluster A nnAbs stabilize an asymmetric Env conformation, State 2A, and have potent ADCC activity. CRF01_AE strains were suggested to be intrinsically susceptible to ADCC mediated by nnAbs. This may be due to the presence of a histidine at position 375, known to shift Env towards more “open” conformations. In this work, through adaptation of an established smFRET imaging approach, we report that the conformational dynamics of native, unliganded HIV-1_{CRF01_AE} Env indicates frequent sampling of the State 2A conformation. This is in striking contrast with Envs from clades A and B, for example HIV-1_{JR-FL}, which do not transition to State 2A in the absence of ligands. These findings inform on the conformational dynamics of HIV-1_{CRF01_AE} Env, which are relevant for structure-based design of both synthetic inhibitors of receptor binding, and enhancers of ADCC as therapeutic alternatives.

IMPORTANCE

A concerning increase in infections with HIV-1_{CRF01_AE} has occurred globally and regionally in recent years, especially in Southeast Asia. Despite the advances made in understanding HIV-1 Env conformational dynamics, the knowledge about Env from HIV-1_{CRF01_AE} is limited. Here, we demonstrate that HIV-1_{CRF01_AE} Env readily samples an open conformation (State 2A), which is susceptible to ADCC. This is in contrast with the subtypes previously studied from HIV-1 group M that rely on anti-cluster A antibodies to adopt State 2A. These findings are relevant for the structure-based design of novel

synthetic inhibitors of CD4 binding and enhancers of ADCC for elimination of infected cells.

KEYWORDS: smFRET, HIV, Env, CRF01_AE, ADCC.

INTRODUCTION

The RV144 HIV-1 vaccine trial in Thailand, which concluded in 2009, elicited a 31.2% protective efficacy. Subsequent analyses indicated that this modest protection was correlated with antibodies (Abs) with Ab-dependent cellular cytotoxicity (ADCC) activity specific to the HIV-1 envelope glycoprotein (Env) in a subset of individuals with low plasma IgA (1, 2). This suggests that ADCC may have contributed to the protection observed in the RV144 trial. HIV-1 strains of the circulating recombinant form AE (CRF01_AE) predominate the AIDS epidemic in Southeast Asia (3). Therefore, the RV144 trial utilized glycoproteins from two CRF01_AE strains as immunogens. Moreover, the prevalence of HIV-1 CRFs has risen in recent years, most significantly in Southeast Asia (4). For these reasons, detailed investigation of Env from HIV-1 CRFs is warranted. While advances in the understanding of Env conformational dynamics have been achieved using virological and biophysical approaches, these studies have focused on HIV-1 subtypes A and B (5–11). A similar elucidation of the dynamics of Env from HIV-1 CRFs has not been reported. However, prior studies demonstrated an inherent susceptibility of HIV-1_{CRF01_AE} to ADCC, which begins to explain the results of the RV144 trial (12). Subsequent structural investigation of HIV-1_{CRF01_AE} Env indicated features that are distinct from other subtypes and perhaps enable conformations related to recognition by Abs with ADCC activity (13). In the present study, we explore the conformational features of Env from HIV-1_{CRF01_AE} and their relationship to ADCC mediated by plasma from people living with HIV (PLWH).

The first step in replication of HIV-1 is the binding of Env to the cellular receptor CD4. Env is synthesized as the gp160 precursor, which is trimerized and glycosylated in the endoplasmic reticulum of infected cells (14, 15), followed by proteolytic processing by host furin-like proteases in the Golgi apparatus (16–18). The resulting cleaved and mature Env trimer is comprised of three gp120 subunits, which are non-covalently associated with three transmembrane gp41 subunits [(gp120-gp41)₃] (19–21). Mature Env is present on virions as well as exposed on the surface of infected cells, making it the primary target of host Abs. Some Abs neutralize the virus (NAbs) by blocking Env's interaction with receptors or inhibiting conformational changes needed to promote fusion of the viral and cellular membranes. Other Abs that are frequently elicited during

HIV-1 infection, including in people living with HIV (PLWH), are non-neutralizing (nnAbs) since they recognize Env targets occluded within closed Env conformations. Certain classes of nnAbs, however, can induce the death of infected cells through ADCC, provided Env samples an “open” conformation (22).

Single-molecule Förster resonance energy transfer (smFRET) imaging studies demonstrated that Env is highly dynamic, transitioning from a “closed” conformation (State 1) to an “open” conformation (State 3), which is promoted through the interaction with CD4. An asymmetric intermediate (State 2) of Env can be observed during the transition from State 1 to State 3 (9, 11). The Env conformational equilibrium from primary HIV-1 isolates of clades A and B favor State 1 in the absence of ligands, which confers resistance to most Abs, especially those that target CD4-induced (CD4i) epitopes (11, 23). Nonetheless, some broadly neutralizing Abs (bNAbs) preferentially bind this closed conformation (7, 11). However, after interacting with cellular CD4, Env adopts State 3, exposing cryptic epitopes including the coreceptor-binding site (CoRBS) and cluster A region, which can be targeted by nnAbs to promote ADCC (5, 23–28). CD4-mimetic compounds (CD4mcs) are small molecules designed to target specifically the CD4 binding cavity within HIV-1 Env. CD4mcs can induce conformational changes in Env that sensitize it to recognition by nnAbs (25, 26). In the presence of soluble CD4 (sCD4) or CD4mcs, anti-CoRBS and anti-cluster A Abs stabilize State 2A, which is an asymmetric Env conformation associated with increased ADCC responses *in vitro* and Fc-effector functions *in vivo* (8, 25, 29–31).

The findings presented here indicate that native HIV-1_{CRF01_AE} Env intrinsically presents the State 2A conformation, which is susceptible to ADCC even in the absence of CD4 or CD4mcs. This contrasts with clade-B HIV-1_{JR-FL} Env, which depends on incubation with CD4 or CD4mcs, and antibodies targeting the CoRBS to adopt State 2A (8, 25). Interaction of HIV-1_{CRF01_AE} Env with CD4 and CoRBS Abs further stabilized State 2A. The conformational features of HIV-1_{CRF01_AE} Env warrants further research to identify the structural determinants or elements that govern its dynamic equilibrium. Targeting cells infected with HIV-1_{CRF01_AE} could represent a promising strategy for elimination of infected cells (31–33).

RESULTS

HIV-1_{CRF01_AE} is more susceptible to ADCC than a representative subtype B strain

We made a direct comparison of the susceptibility of infected cells to ADCC using representative infectious molecular clones (IMCs) from CRF01_AE (strain 703357) and subtype B (strain JR-FL). First, we evaluated the binding capacity of plasma from ten PLWH (Table 1). No significant differences between the two strains were observed (**Fig. 1A**). However, the ADCC responses to HIV-1_{CRF01_AE} were approximately two-fold higher than that observed with HIV-1_{JR-FL} strain (**Fig. 1B**). Because activation of the ADCC response has been associated with a specific conformation of HIV-1 Env that enables binding of a specific class of Abs, these results suggest that HIV-1_{CRF01_AE} Env may have distinct conformational features that confer the sensitivity to ADCC (5, 6).

Modifications in HIV-1_{CRF01_AE} Env that enable site-specific fluorescent labeling do not affect viral infectivity

With the aim of visualizing the conformational dynamics of HIV-1_{CRF01_AE} Env, we adapted a previously validated smFRET imaging assay. Insertion of the A4 peptide (DSLDMLEW) and incorporation of non-natural amino acids (nnAAs) into HIV-1 Env facilitate fluorophore attachment. These methods have been applied with minimal effect on functionally to subtype-B HIV-1 strains NL4-3 and JR-FL, as well as the subtype-A strain BG505 (7–9, 11, 30). As for previous applications, we attached site-specifically fluorophores in the V1 and V4 loops of a single gp120 domain within HIV-1_{CRF01_AE} Env on the surface of pseudovirions (**Fig. 2A**). To this end, we inserted the A4 peptide next to V135 in V1 (V1-A4), which enabled enzymatic attachment of the LD650 fluorophore. We also substituted an amber stop codon for amino acid N398 in V4 of gp120 (V4-N398^{TAG}). Suppression of the amber stop codon incorporates the nnAA TCO*, which facilitated Cy3 fluorophore attachment through copper-free click chemistry (**Fig. 2B**) (34).

We next confirmed full-length translation of the HIV-1_{CRF01_AE} Env containing the V1-A4 and V4-N398^{TAG} mutations (tagged) and its incorporation into virions. We evaluated through immunoblots the abundance of both full-length gp120 and the HIV-1 core capsid protein p24 in purified viral preparations (**Fig. 2C**). As expected, tagged

gp120 was not detected in virions produced in the absence of the nnAA TCO* and the corresponding aminoacyl tRNA synthetase and suppressor tRNA, which codes for the amber stop codon. This indicates that readthrough of the amber codon in the V4 loop did not occur, resulting in the lack of Env incorporation into viral particles (**Fig. 2C**, top immunoblot, lane 4). However, in the presence of TCO*, the synthetase, and the suppressor tRNA, tagged gp120 was detected in virions at a comparable level as wild-type Env (**Fig. 2C**, top immunoblot, lane 5). We next verified that V1-A4/V4-N398^{TAG} modifications in Env do not alter virus infectivity. Virus preparations bearing wild-type or tagged Env showed no statistically significant difference in their infectivity in TZM-bl cells (**Fig. 2D**), suggesting that both incorporation of the A4 peptide in V1 and the nnAA TCO* in V4 does not affect the function of Env. Altogether, these data demonstrate that tagged Env is incorporated into pseudovirions and maintains native function during infection of cells.

Native HIV-1_{CRF01_AE} Env intrinsically samples open conformations

We next sought to evaluate the conformational dynamics in real-time of individual HIV-1_{CRF01_AE} Env molecules on the surface of virions using smFRET imaging. To this end, we prepared virions bearing a single fluorescently labeled gp120 domain as described for Env from other HIV-1 strains (**Fig. 2A**) (7–9, 11). Labelled virions were immobilized on passivated quartz microscope slides and imaged using prism-based total internal reflection fluorescence (TIRF) microscopy. We used the well-characterized HIV-1_{JR-FL} Env as a point of comparison. As previously described, the application of hidden Markov modeling (HMM) for analysis of the smFRET trajectories enabled the identification of four FRET states (**Fig. 3A**). For both HIV-1_{CRF01_AE} and HIV-1_{JR-FL} Env, the predominant low-FRET value (0.22 ± 0.1 FRET [mean $\pm$ standard deviation], State 1) is associated with a closed Env conformation (**Fig. 3A-B, Table 2**). Quantification of the mean occupancies in State 1 across the populations of molecules indicated $68 \pm 2\%$ and $42 \pm 2\%$ ($p < 10^{-4}$) for HIV-1_{JR-FL} and HIV-1_{CRF01_AE}, respectively. We also observed State 3 (0.45 ± 0.1 FRET) for both strains, which is associated with an open Env conformation. We determined State 3 occupancies of $32 \pm 2\%$ and $27 \pm 2\%$ ($p = 0.6$) for HIV-1_{JR-FL} and HIV-1_{CRF01_AE}, respectively. Consistent with previous reports, we detected minimal

occupancy for HIV-1_{JR-FL} Env in States 2 and 2A (0.70 ± 0.1 and 0.85 ± 0.1 FRET, respectively). In striking contrast, HIV-1_{CRF01_AE} Env displayed $19 \pm 2\%$ occupancy in State 2 and $12 \pm 1\%$ in State 2A in the absence of bound ligands. These data demonstrate that HIV-1_{CRF01_AE} Env has greater intrinsic access to open conformations than HIV-1_{JR-FL} Env.

We next asked if sCD4 consisting of soluble domain 1 and 2 (sCD4^{D1D2}) or the anti-CoRBS 17b mAb, further stabilize open conformations. For both HIV-1_{JR-FL} and HIV-1_{CRF01_AE} Env, the addition of sCD4^{D1D2} destabilized State 1 and promoted transition to the higher FRET states (**Fig. 3A-B, Table 2**). For HIV-1_{JR-FL} Env, we observed increased occupancy in States 2 and 3, as previously reported (11). sCD4^{D1D2} had only a modest effect on HIV-1_{CRF01_AE} Env conformation, with only a slight stabilization of State 3. Addition of both sCD4^{D1D2} and 17b further promoted State 3 for HIV-1_{JR-FL} Env, as expected. In contrast, the predominant effect of sCD4^{D1D2}/17b on HIV-1_{CRF01_AE} Env was to stabilize State 2A, increasing the occupancy to $17 \pm 2\%$. These data demonstrate that sCD4^{D1D2} only minimally promotes open conformations of HIV-1_{CRF01_AE} Env beyond that seen in the absence of ligands. However, HIV-1_{CRF01_AE} Env readily adopts State 2A in the presence of sCD4^{D1D2} and 17b. Access to State 2A correlates with the inherent sensitivity to ADCC seen for HIV-1_{CRF01_AE}.

DISCUSSION

During HIV-1 infection, the humoral response against Env mainly produces antibodies that are non-neutralizing. Despite the lack of neutralization, nnAbs can still trigger ADCC to clear infected cells, provided that Env is exposed in an “open” conformation (35). Env glycoproteins from most HIV-1 strains naturally adopt State 1, which is associated with a closed conformation (11), and confers resistance to nnAbs (23, 36). In contrast, previous functional studies suggested that Env glycoproteins from HIV-1_{CRF01_AE} subtypes intrinsically adopt open conformations even in the absence of CD4, CD4 mimetics, or anti-CoRBS mAbs (5, 6, 12). Recent insights from structural data further support this idea (13). Here, we have shown that plasma obtained from PLWH triggers ADCC against HIV-1_{CRF01_AE} infected cells to a greater extent than HIV-1_{JR-FL} infected cells. We therefore sought to directly test the conformational equilibrium of HIV-1_{CRF01_AE} Env using smFRET imaging. We have demonstrated through real-time analysis of HIV-1_{CRF01_AE} Env conformational dynamics that this glycoprotein intrinsically samples open conformations in the absence of bound ligands. HIV-1_{CRF01_AE} 92TH023 Env intrinsically adopts State 2A, which was previously linked to exposure of both the CoRBS and cluster A epitopes that are targeted by Abs with potent ADCC activity (8). Addition of sCD4^{D1D2}, with or without 17b, stabilized State 2A to a greater extent than seen for HIV-1_{JR-FL} Env. The results presented here were obtained with Env from HIV-1_{CRF01_AE} strain 92TH023. Additional effort should be devoted to generalizing these results to Envs from additional CRF01_AE strains. Nevertheless, the data presented here provide a means of interpreting the inherent sensitivity of HIV-1_{CRF01_AE} to ADCC in terms of the conformation of Env. These data also provide new understanding for the role of vaccine-induced Abs that mediated ADCC during the RV144 trial in Thailand, where HIV-1_{CRF01_AE} predominates (5). To conclude, our data strongly underscore the importance of considering Env conformational diversity across different HIV-1 clades when designing more effective HIV-1 interventions and vaccine strategies. This is of particular importance for the development of tailored strategies for enhancing ADCC against HIV-1_{CRF01_AE}, which offers promising avenues for the elimination of cells infected with this prevalent strain in Southeast Asia.

MATERIALS AND METHODS

Ethics statement

Written informed consent was obtained from all study participants, and the research adhered to the ethical guidelines of CRCHUM and was reviewed and approved by the CRCHUM Institutional Review Board (Ethics Committee approval number MP-02-2024-11734). The research adhered to the standards indicated by the Declaration of Helsinki. All participants were adults and provided informed written consent prior to enrollment, in accordance with the Institutional Review Board approval.

Plasma samples

The FRQS-AIDS and Infectious Diseases Network supports a representative cohort of newly-HIV-infected subjects with clinical indication of primary infection [the Montreal Primary HIV Infection Cohort]. Plasma samples from ten deidentified PLWH donors were heat-inactivated and stored as previously described (24, 26).

Cell lines and primary cells

ExpiCHO-S cells (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) were cultured in ExpiCHO Expression media (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) at 37 °C, 8% CO₂ with orbital shaking according to manufacturer instructions. The cell line HEK293T-FIRB with enhanced furin expression was a kind gift from Dr. Theodore C. Pierson (Emerging Respiratory Virus section, Laboratory of Infectious Diseases, NIH, Bethesda, MD), and was cultured at 37°C, 5% CO₂ in complete DMEM made of DMEM (Gibco, ThermoFisher Scientific, Waltham, MA, USA) supplemented with 10% (v/v) cosmic calf serum (Hyclone, Cytiva Life Sciences, Marlborough, MA, USA), 100 U/ml penicillin, 100 µg/ml streptomycin, and 1 mM glutamine (Gibco, ThermoFisher Scientific, Waltham, MA, USA) (37). The HeLa-derived TZM-bl cell line stably expressing high levels of CD4 and CCR5 receptors and bearing an integrated copy of the luciferase gene under the control of the HIV-1 long-terminal repeat was obtained from the former NIH AIDS Reagent Program (catalog ARP-8129) and cultured in the same conditions as HEK293T-FIRB cells (38).

Human peripheral blood mononuclear cells (PBMCs) from 3 HIV-negative individuals (3 males, age range 40-66 years) obtained by leukapheresis and Ficoll density gradient isolation were cryopreserved in liquid nitrogen until further use. Primary CD4⁺ T cells were purified from resting PBMCs by negative selection using immunomagnetic beads per the manufacturer's instructions (StemCell Technologies, Vancouver, BC) and were activated with phytohemagglutinin-L (PHA-L, 10 µg/mL) for 48h and then maintained in RPMI 1640 (Thermo Fisher Scientific, Waltham, MA, USA) complete medium supplemented with 20% FBS, 100 U/mL penicillin/streptomycin and with recombinant IL-2 (rIL-2, 100 U/mL). All cells were maintained at 37°C under 5% CO₂.

Plasmids and proviral constructs

The plasmid encoding the soluble CD4 domains 1 and 2 (sCD4^{D1D2}) fused to a His6x-tag, as well as the molecular clones of the heavy and light chains of the anti-HIV-1 Env monoclonal antibodies 17b and 2G12, were kindly provided by Dr. Peter Kwong (NIAID, NIH). Plasmids for expression of NESPyIRS^{AF}/hU6tRNA^{Pyl} and eRF1-E55D for the *amber* codon suppression system were previously described (34). The pNL4-3 Δ RT Δ env plasmid has been previously described (11). pNL4-3.Luc.R-E- provirus was obtained from the former NIH AIDS Reagent Program (catalog ARP-3418). The stop codon in *tat* gene of this plasmid was substituted with an *ochre* stop codon as described (39). Plasmids for the expression of full-length HIV-1_{JR-FL} Env wild-type, which was engineered to have an amber (TAG) stop codon at position N135 in the V1 loop of gp120 and the A1 peptide (GDSLDMLEWSLM) in the V4 loop of gp120 (V1-N135^{TAG}/V4-A1) have been previously described (30). The HIV-1_{CRF01_AE} Env expressor has been described (12). This plasmid was engineered to insert the A4 peptide (DSLDMLEW) after residue V135 in the V1 loop of gp120, and substitute an amber codon at position N398 in the V4 loop of gp120 (A4-V1/V4-N398^{TAG}, Fig. 2B). The H375S mutation, was introduced into the untagged and tagged versions of the HIV-1_{CRF01_AE} Env expression plasmids. All the indicated residues in HIV-1_{JR-FL} and HIV-1_{CRF01_AE} Env are numbered according to the HIV-1_{HXBc2} Env sequence.

The infectious molecular clone (IMC) of HIV-1_{JR-FL} was kindly provided by Dr Dennis Burton (The Scripps Research Institute). The CRF01_AE IMC was previously reported (doi: [10.1128/JVI.02452-16](https://doi.org/10.1128/JVI.02452-16)). The sequence of HIV-1_{CRF01_AE} transmitted-founder (T/F) clone 703357 was derived by using a single-genome amplification (SGA) strategy. The entire DNA sequence including both long terminal repeats (LTRs) was cloned into pUC57 to generate a full-length infectious molecular clone (GenBank accession numbers JX448154 and JX448164). The vesicular stomatitis virus G (VSV-G)-encoding plasmid was previously described (46).

Recombinant sCD4^{D1D2} and antibodies

Expression of soluble CD4 domains D1-D2 (sCD4^{D1D2}) fused to a His6x-tag was performed by transfection of ExpiCHO-S™ cells with plasmid using the ExpiFectamine™ CHO transfection kit (Gibco™, Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions. Purification and preparation of this protein was performed with a previously described strategy(40). Briefly, supernatant containing soluble sCD4^{D1D2} was harvested nine days post-transfection and adjusted to 1 mM NiSO₄, 20 mM imidazole, and pH 8.0 before binding to the Ni-NTA resin (Invitrogen™, Waltham, MA, USA). The resin was washed, and sCD4^{D1D2} was eluted from the column with 300 mM imidazole, 500 mM NaCl, 20 mM Tris-HCl pH 8.0, and 10% (v/v) glycerol. Elution fractions containing sCD4^{D1D2} were pooled and concentrated by centrifugal concentrators (Sartorius AG, Göttingen, Germany). Final purification was performed through size exclusion chromatography on a Superdex 200 Increase 10/300 GL column (GE Healthcare, Chicago, IL, USA) followed by concentration as above described.

Expression and preparation of monoclonal antibodies 2G12 and 17b has been described before (40, 41). Briefly, ExpiCHO-S cells were co-transfected with plasmids encoding heavy and light chains using the ExpiFectamine CHO transfection kit (Gibco, ThermoFisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions. Both antibodies were purified from the cell culture supernatant 12 days post-transfection using protein G affinity resin (Thermo Fisher Scientific, Waltham, MA,

USA), subjected to buffer exchange with phosphate buffered saline (PBS) pH 7.4 (Fisher Bioreagents, Thermo Fisher Scientific, Waltham, MA, USA) and concentrated as above described. Mouse monoclonal antibody targeting HIV-1 p24 capsid protein (anti-p24, catalog No. GTX41618) was purchased from Genetex (Irvine, CA, USA). Anti-6x-His-tag polyclonal antibody (catalog No. PA1-983B), horseradish peroxidase (HRP) conjugated anti-human IgG Fc (catalog No. A18823), and anti-mouse IgG Fc (catalog No. 31455) were purchased from Invitrogen™ (Waltham, MA, USA). Goat anti-rabbit IgG antibody conjugated to HRP (catalog No. ab205718) were purchased from Abcam (Cambridge, UK).

Virus production and fluorescent labeling

Non-replicative HIV-1_{CRF01_AE} Env pseudoviruses for infectivity assays were produced by co-transfecting HEK293T-FIRB cells with either a 1:0.005 or 1:1 mass ratio of plasmid pNL4-3.Luc.R-E- *tat_ochre* to wild-type or V1-A4/V4-N398^{TAG} tagged version of HIV-1_{CRF01_AE} Env expressors, respectively. Plasmids encoding NESPyIRS^{AF}/hU6tRNA^{Pyl} and eRF1-E55D were also included along with 0.5 mM TCO* (SiChem GmbH, Bremen, Germany) as previous described (30, 39, 42, 43). Virus was collected 48 hours post-transfection and pelleted over a 10% sucrose cushion at 25,000 RPM for 2 hours at 4 °C using a SW32Ti rotor (Beckman Coulter Life Sciences, Brea, CA, USA). Pellets were resuspended in DMEM (Gibco ThermoFisher Scientific, Waltham, MA, USA), aliquoted, and stored at -80 °C until use.

For smFRET imaging, non-replicative HIV-1_{JR-FL} and HIV-1_{CRF01_AE} Env pseudovirions with a single gp120 domain bearing the above-mentioned modifications in the V1 and V4 loops, were also produced in the presence of TCO* as previously described (30). Briefly, HEK-293T FIRB cells were co-transfected with plasmids NESPyIRS^{AF}/hU6tRNA^{Pyl} and eRF1-E55D, in addition of pNL4-3 ΔRT ΔEnv, and a 20:1 mass ratio of HIV-1_{JR-FL} or HIV-1_{CRF01_AE} Env wild-type expressor to the corresponding tagged version. Virus was collected 48 hours post-transfection and pelleted as above. Virus pellets was then resuspended in labeling buffer (50 mM HEPES pH 7.0, 10 mM CaCl₂, 10 mM MgCl₂), and incubated overnight at room temperature with 5 μM LD650-coenzyme A (Lumidyne Technologies, New York, NY, USA), and 5 μM acyl carrier protein

synthase (AcpS), which labels the A1 (or A4) peptide. Virus was then incubated with 0.5 μ M Cy3-tetrazine (Jena Biosciences, Jena, Germany) for 30 min at room temperature, followed by incubation with 60 μ M DSPE-PEG2000-biotin (Avanti Polar Lipids, Alabaster, AL, USA) for an additional 30 min at room temperature. Finally, labelled virus was purified through ultracentrifugation for 1 hour at 35,000 RPM using a rotor SW40Ti (Beckman Coulter Life Sciences, Brea, CA, USA), at 4 °C in a 6–30% OptiPrep (Sigma-Aldrich, MilliporeSigma, Burlington, MA, USA) density gradient. Labelled pseudovirions were collected, analyzed by anti-p24 Western blot, aliquoted, and stored at -80°C until their use in imaging experiments.

Immunoblots

HIV-1 gp120 and p24 proteins, or sCD4^{D1D2} were detected through immunoblot assays as follows. Samples were mixed with 4X Laemmli sample buffer (Bio-Rad, Hercules, CA, USA) supplemented with 2-mercaptoethanol (Fisher Chemical, Hampton, NH, USA) and heated for 5 min at 98 °C. Proteins were then resolved by denaturing PAGE using 4-20% acrylamide gels (Bio-Rad, Hercules, CA, USA). Proteins were then transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) according to the manufacturer's instructions. After blocking for one hour at room temperature with 5% (w/v) skim milk in PBS-T buffer [PBS and 0.1% (v/v) Tween™-20, Fisher Scientific, Hampton, NH, USA], membranes were incubated overnight at 4 °C with the indicated primary antibodies diluted in blocking buffer. Detection of gp120 was achieved by using a 3 μ g/ml dilution of 2G12, while detection of p24 and sCD4^{D1D2} was performed with 2 μ g/ml dilutions of anti-p24 mAb (GeneTex, Irvine, CA, USA) or rabbit anti-6x-His-tag polyclonal antibody (Invitrogen™, Waltham, MA, USA), respectively. Membranes were washed three times with PBS-T and incubated for one hour at room temperature with a 1/10,000 dilution (v/v) in 0.5% (w/v) skim milk/PBS-T of HRP-conjugated anti-human IgG Fc or anti-mouse IgG Fc (Invitrogen™, Waltham, MA, USA) antibodies for membranes incubated with 2G12 or anti-p24 mAbs, respectively, or a 1/50,000 dilution of HRP-conjugated anti-rabbit IgG antibody (Abcam, Cambridge, UK) was used for membranes incubated with anti-His6X antibody. After three washes with PBS-T, membranes were developed using SuperSignal™ West Pico PLUS Chemiluminescent

Substrate (Thermo Scientific™, Waltham, MA, USA) according to the manufacturer's instructions.

Infectivity assays

2.5x10⁴ TZM-bl cells/well were seeded 24 hours before the assay in 24-well plates. Cells were then washed once with DMEM (Gibco, ThermoFisher Scientific, Waltham, MA, USA) and inoculated with pseudo-typed lentiviruses bearing wild-type or tagged HIV-1_{CRF01_AE} Env. After 2 h of virus adsorption at 37 °C, viral inoculums were removed and cells were washed with DMEM, followed by addition of fresh complete phenol red-free DMEM (Gibco, ThermoFisher Scientific, Waltham, MA, USA). Cell supernatants were removed 48 hours post-infection. The cells were lysed with Glo Lysis Buffer (Promega, Madison, WI, USA) according to the manufacturer's instructions. Luciferase activity in cell lysates was detected by mixing equal volumes of lysate and Steady-Glo Luciferase Assay System reagent (Promega, Madison, WI, USA) and measured on a Synergy H1 microplate reader (Biotek, Winooski, VT, USA). The luminescence signal from mock infected cell lysates was subtracted from the signal obtained from infected cells and normalized by the abundance of both envelope gp120 and p24 proteins in viral inoculums, which were determined through densitometric analysis of protein bands observed in immunoblots using ImageJ software v1.52q (NIH, Bethesda, MD, USA). Infectivity was expressed as the percentage of that seen in cells inoculated with wild-type HIV-1_{CRF01_AE} Env pseudovirions.

smFRET Imaging

Labelled HIV-1_{JR-FL} or HIV-1_{CRF01_AE} Env pseudovirions were immobilized on streptavidin-coated quartz slides and imaged on a custom-built wide-field prism-based TIRF microscope (39, 44). Where indicated, pseudovirions were incubated with 50 µM sCD4^{D1D2} and 50 µg/ml 17b mAb for 1 hour at room temperature prior to surface immobilization. Imaging was performed in phosphate-buffered saline (PBS) pH ~7.4, containing 1 mM trolox (Sigma-Aldrich, St. Louis, MO, USA), 1 mM cyclooctatetraene (COT; Sigma-Aldrich, St. Louis, MO, USA), 1 mM 4-nitrobenzyl alcohol (NBA; Sigma-Aldrich, St. Louis, MO, USA), 2 mM protocatechuic acid (PCA; Sigma-Aldrich, St. Louis,

MO, USA), and 8 nM protocatechuate 3,4-deoxygenase (PCD; Sigma-Aldrich, St. Louis, MO, USA) to stabilize fluorescence and remove molecular oxygen. When indicated, concentrations of sCD4^{D1D2} and mAb 17b were maintained during imaging. smFRET data were collected using Micromanager v2.0 at 25 frames/sec, processed, and analyzed using SPARTAN software in Matlab (Mathworks, Natick, MA, USA) (45). smFRET traces were identified according to criteria previously described (8); traces meeting those criteria were verified manually. FRET histograms were generated by compiling traces from each of three technical replicates and the mean probability per histogram bin $\pm$ standard error was calculated. Traces were idealized to a five-state HMM (four nonzero-FRET states and a zero-FRET state) using the maximum point likelihood (MPL) algorithm (46). The idealizations were used to determine the occupancies (fraction of time until photobleaching) in each FRET state, and construct Gaussian distributions of each FRET state, which were overlaid on the FRET histograms to visualize the results of the HMM analysis. The distributions in occupancies were used to construct violin plots in Matlab, as well as calculation of mean occupancies and standard errors.

Viral production and infection of primary CD4⁺ T cells

VSV-G-pseudotyped HIV-1 viruses were produced by co-transfection of 293T cells with the HIV-1_{JRFL} or HIV-1_{CR01AE} proviral construct and a VSV-G-encoding vector at a ratio of 3:2 using the polyethylenimine (PEI) method. Two days post-transfection, cell supernatants were harvested, clarified by low-speed centrifugation (300 $\times$ g for 5 min), and concentrated by ultracentrifugation at 4°C (100,605 $\times$ g for 1h) over a 20% sucrose cushion. Pellets were resuspended in fresh RPMI 1640 complete medium, aliquoted and stored at -80°C until use.

Primary CD4⁺ T cells from HIV-1 negative individuals were isolated from PBMCs, activated for 2 days with PHA-L and then maintained in RPMI 1640 complete medium supplemented with rIL-2. Five to seven days after activation, the cells were spinoculated with the virus at 800 $\times$ g for 1h in 96-well plates at 25°C. All viral productions were titrated on primary CD4⁺ T cells to achieve similar levels of infection (around 20% of infected cells).

Flow cytometry analysis of cell-surface staining

Forty-eight hours after infection, HIV-1-infected primary CD4⁺ T cells were collected, washed with PBS and transferred in 96-well V-bottom plates. The cells were then incubated for 45 min at 37°C with plasma (1:1000 dilution). Cells were then washed twice with PBS and stained with anti-human IgG Alexa Fluor 647-conjugated secondary antibody (2 µg/mL), FITC-conjugated mouse anti-human CD4 (Clone OKT4) Antibody (1:500 dilution) and AquaVivid viability dye (Thermo Fisher Scientific, Cat# L43957) for 20 min at room temperature. Alexa-Fluor-conjugated anti-human IgG Fc secondary antibodies (1:1500 dilution) were used as secondary antibodies. Cells were then washed twice with PBS and fixed in a 2% PBS-formaldehyde solution. The cells were then permeabilized using the Cytotfix/Cytoperm Fixation/Permeabilization Kit (BD Biosciences, Mississauga, ON, Canada) and stained intracellularly using PE-conjugated mouse anti-p24 mAb (clone KC57; Beckman Coulter, Brea, CA, USA; 1:100 dilution). Samples were acquired on an Fortessa cytometer (BD Biosciences), and data analysis was performed using FlowJo v10.5.3 (Tree Star, Ashland, OR, USA). The percentage of productively infected cells (p24⁺ CD4⁺) was determined by gating on the living cell population according to viability dye staining (Aqua Vivid; Thermo Fisher Scientific).

ADCC assay

ADCC activity was measured using a FACS-based infected cell elimination assay 48 hours after infection. The HIV-1-infected primary CD4⁺ T cells were stained with AquaVivid viability dye and cell proliferation dye eFluor670 (Thermo Fisher Scientific) and used as target cells. Resting autologous PBMCs, were stained with cell proliferation dye eFluor450 (Thermo Fisher Scientific) and used as effectors cells. The HIV-1-infected primary CD4⁺ T cells were co-cultured with autologous PBMCs (Effector: Target ratio of 10:1) in 96-well V-bottom plates in the presence of plasma from PLWH (dilution 1:1000) for 5h at 37°C. After the 5h incubation, cells were then washed once with PBS and stained with FITC-conjugated mouse anti-human CD4 (Clone OKT4) antibody for 10 min at room temperature. Cells were then washed twice with PBS and fixed in a 2% PBS-formaldehyde solution. The cells were then permeabilized and

stained intracellularly for p24 as described above. Samples were acquired on a Fortessa cytometer (BD Biosciences), and data analysis was performed using FlowJo v10.5.3 (Tree Star, Ashland, OR, USA). The percentage of infected cells (p24⁺ CD4⁻) was determined by gating on the living cell population according to viability dye staining (Aqua Vivid; Thermo Fisher Scientific). The percentage of ADCC was calculated with the following formula: $[(\% \text{ of p24}^+ \text{CD4}^- \text{ cells in Targets plus Effectors}) - (\% \text{ of p24}^+ \text{CD4}^- \text{ cells in Targets plus Effectors plus plasma})] / (\% \text{ of p24}^+ \text{CD4}^- \text{ cells in Targets}) \times 100$.

Statistical analysis

Statistics for infectivity assays were determined using GraphPad Prism version 10.2.3 (GraphPad, San Diego, CA, USA). Every data set was tested for statistical normality and this information was used to apply the appropriate (parametric or nonparametric) statistical test. Statistical significance measures (*p*-values) of FRET state occupancies were determined by one-way ANOVA followed by multiple comparison testing in Matlab (The MathWorks, Waltham, MA, USA). In all cases, *p*-values <0.05 were considered statistically significant.

Acknowledgements

The authors thank Dr. Robert Blakemore for assistance in the design of the tagged HIV-1_{CRF01_AE} Env glycoprotein, Dr. Dennis Burton (The Scripps Research Institute) for HIV-1_{JRFL}, and Dr. Peter Kwong (NIAID, NIH) for providing the molecular clones of sCD4^{D1D2}, and mAbs 2G12 and 17b heavy and light chains. The TZM-bl cell line (ARP-8129) was obtained through the former NIH HIV Reagent Program, Division of AIDS, NIAID, NIH, and this cell line was originally contributed to them by Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. M.N. was supported by a ViiV postdoctoral fellowship. J.P. was supported by a CIHR fellowship. This work was supported by NIH grant R01AI150322 (to J.B.M. and A.F.).

Author Contributions

J.B.M. and A.F. conceived of the study. M.A.D.-S., D.C., M.N., H.M., J.P., M.P., A.F., and J.B.M. designed experimental approaches, performed, analyzed, and

interpreted the experiments. A.F., and J.B.M. obtained the funding and supervised the research. M.A.D.-S., and J.B.M. wrote the manuscript. All authors have read, edited, and approved the final manuscript.

Disclaimer

The views expressed in this manuscript are those of the authors and do not reflect the official policy or position of the Uniformed Services University, US Army, the Department of Defense, or the US Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of Interest

The authors declare no competing interests.

Data Availability

All data generated or analyzed during this study are included in the manuscript.

REFERENCES

1. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao H-X, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngaui V, Souza MS de, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, Rosa SCD, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. *New Engl J Medicine* 366:1275 1286.
2. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao H-X, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, Poling B, Nicholson CO, Zhang R, Lu X, Parks R, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Gilbert PB, Kim JH, Michael NL, Montefiori DC, Haynes BF. 2013. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. *Proc National Acad Sci* 110:9019 9024.
3. Gao F, Robertson DL, Morrison SG, Hui HX, Craig S, Decker J, Fultz PN, Girard M, Shaw GM, Hahn BH, Sharp PM. 1996. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. *Journal of virology* 70:7013 7029.
4. Hemelaar J, Elangovan R, Yun J, Dickson-Tetteh L, Kirtley S, Gouws-Williams E, Ghys PD, Abimiku AG, Agwale S, Archibald C, Avidor B, Barbás MG, Barre-Sinoussi F, Barugahare B, Belabbes EH, Bertagnolio S, Birx D, Bobkov AF, Brandful J, Bredell H, Brennan CA, Brooks J, Bruckova M, Buonaguro L, Buonaguro F, Buttò S, Buvé A, Campbell M, Carr J, Carrera A, Carrillo MG, Celum C, Chaplin B, Charles M, Chatzidimitriou D, Chen Z, Chijiwa K, Cooper D, Cunningham P, Dagnra A, Gascun CF de, Amo JD, Delgado E, Dietrich U, Dwyer D, Ellenberger D, Ensoli B, Essex M, Gao F, Fleury H, Fonjongo PN, Foulongne V, Gadkari DA, Gao F, García F, Garsia R, Gershys-Damet GM, Glynn JR, Goodall R, Grossman Z, Lindenmeyer-Guimarães M, Hahn B, Hamers RL, Hamouda O, Handema R, He X, Herbeck J, Ho DD, Holguin A, Hosseinipour M, Hunt G, Ito M, Kacem MABH, Kahle E, Kaleebu P, Kalish M, Kamarulzaman A, Kang C, Kanki P, Karamov E, Karasi J-C, Kayitenkore K, Kelleher T, Kitayaporn D, Kostrikis LG, Kucherer C, Lara C, Leitner T, Liitsola K, Lingappa J, Linka M, Rivera IL de, Lukashov V, Maayan S, Mayr L, McCutchan F, Meda N, Menu E, Mhalu F, Mloka D, Mokili JL, Montes B, Mor O, Morgado M, Mosha F, Moussi A, Mullins J, Najera R, Nasr M, Ndembu N, Neilson JR, Nerurkar VR, Neuhann F, Nolte C, Novitsky V, Nyambi P, Ofner M, Paladin FJ, Papa A, Pape J, Parkin N, Parry C, Peeters M, Pelletier A, Pérez-Álvarez L, Pillay D, Pinto A, Quang TD, Rademeyer C, Raikanikoda F, Rayfield MA, Reynes J-M, Wit TR de, Robbins KE, Rolland M, Rousseau C, Salazar-Gonzales J, Salem H, Salminen M, Salomon H, Sandstrom P, Santiago ML, Sarr AD, Schroeder B, Segondy M, Selhorst P, Sempala S, Servais J, Shaik A, Shao Y, Slim A, Soares MA, Songok E, Stewart D, Stokes J, Subbarao S,

- Sutthent R, Takehisa J, Tanuri A, Tee KK, Thapa K, Thomson M, Tran T, Urassa W, Ushijima H, Perre P van de, Groen G van der, Laethem K van, Oosterhout J van, Sighem A van, Wijngaerden E van, Vandamme A-M, Vercauteren J, Vidal N, Wallace L, Williamson C, Wolday D, Xu J, Yang C, Zhang L, Zhang R. 2020. Global and regional epidemiology of HIV-1 recombinants in 1990–2015: a systematic review and global survey. *Lancet HIV* 7:e772–e781.
5. Prévost J, Zoubchenok D, Richard J, Veillette M, Pacheco B, Coutu M, Brassard N, Parsons MS, Ruxrungtham K, Bunupuradah T, Tovnanabutra S, Hwang K-K, Moody MA, Haynes BF, Bonsignori M, Sodroski J, Kaufmann DE, Shaw GM, Chenine AL, Finzi A. 2017. Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. *J Virol* 91:e02452-16.
6. Prévost J, Tolbert WD, Medjahed H, Sherburn RT, Madani N, Zoubchenok D, Gendron-Lepage G, Gaffney AE, Grenier MC, Kirk S, Vergara N, Han C, Mann BT, Chénine AL, Ahmed A, Chaiken I, Kirchhoff F, Hahn BH, Haim H, Abrams CF, Smith AB, Sodroski J, Pazgier M, Finzi A. 2020. The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and the CD4 Binding Site. *mBio* 11:e00280-20.
7. Lu M, Ma X, Castillo-Menendez LR, Gorman J, Alsahafi N, Ermel U, Terry DS, Chambers M, Peng D, Zhang B, Zhou T, Reichard N, Wang K, Grover JR, Carman BP, Gardner MR, Nikić-Spiegel I, Sugawara A, Arthos J, Lemke EA, Smith AB, Farzan M, Abrams C, Munro JB, McDermott AB, Finzi A, Kwong PD, Blanchard SC, Sodroski JG, Mothes W. 2019. Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET. *Nature* 568:1–5.
8. Alsahafi N, Bakouche N, Kazemi M, Richard J, Ding S, Bhattacharyya S, Das D, Anand SP, Prévost J, Tolbert WD, Lu H, Medjahed H, Gendron-Lepage G, Delgado GGO, Kirk S, Melillo B, Mothes W, Sodroski J, Smith AB, Kaufmann DE, Wu X, Pazgier M, Rouiller I, Finzi A, Munro JB. 2019. An Asymmetric Opening of HIV-1 Envelope Mediates Antibody-Dependent Cellular Cytotoxicity. *Cell Host Microbe* 25:578-587.e5.
9. Ma X, Lu M, Gorman J, Terry DS, Hong X, Zhou Z, Zhao H, Altman RB, Arthos J, Blanchard SC, Kwong PD, Munro JB, Mothes W. 2018. HIV-1 Env trimer opens through an asymmetric intermediate in which individual protomers adopt distinct conformations. *Elife* 7:1826.
10. Herschhorn A, Ma X, Gu C, Ventura JD, Castillo-Menendez L, Melillo B, Terry DS, Smith AB, Blanchard SC, Munro JB, Mothes W, Finzi A, Sodroski J. 2016. Release of gp120 Restraints Leads to an Entry-Competent Intermediate State of the HIV-1 Envelope Glycoproteins. *Mbio* 7:e01598-16.
11. Munro JB, Gorman J, Ma X, Zhou Z, Arthos J, Burton DR, Koff WC, Courter JR, Smith AB, Kwong PD, Blanchard SC, Mothes W. 2014. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. *Science* 346:759 763.

606 12. Zoubchenok D, Veillette M, Prévost J, Sanders-Buell E, Wagh K, Korber B, Chenine
607 AL, Finzi A. 2017. Histidine 375 Modulates CD4 Binding in HIV-1 CRF01_AE Envelope
608 Glycoproteins. *J Virol* 91:e02151-16.

609 13. Prévost J, Chen Y, Zhou F, Tolbert WD, Gasser R, Medjahed H, Nayrac M, Nguyen
610 DN, Gottumukkala S, Hessel AJ, Rao VB, Pozharski E, Huang RK, Matthies D, Finzi A,
611 Pazgier M. 2023. Structure-function analyses reveal key molecular determinants of HIV-
612 1 CRF01_AE resistance to the entry inhibitor temsavir. *Nat Commun* 14:6710.

613 14. Checkley MA, Luttge BG, Freed EO. 2011. HIV-1 Envelope Glycoprotein
614 Biosynthesis, Trafficking, and Incorporation. *J Mol Biol* 410:582–608.

615 15. Willey RL, Bonifacino JS, Potts BJ, Martin MA, Klausner RD. 1988. Biosynthesis,
616 cleavage, and degradation of the human immunodeficiency virus 1 envelope
617 glycoprotein gp160. *Proc Natl Acad Sci* 85:9580–9584.

618 16. Earl PL, Doms RW, Moss B. 1990. Oligomeric structure of the human
619 immunodeficiency virus type 1 envelope glycoprotein. *Proc Natl Acad Sci* 87:648–652.

620 17. Freed EO, Myers DJ, Risser R. 1989. Mutational analysis of the cleavage sequence
621 of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. *J*
622 *Virol* 63:4670–4675.

623 18. McCune JM, Rabin LB, Feinberg MB, Lieberman M, Kosek JC, Reyes GR,
624 Weissman IL. 1988. Endoproteolytic cleavage of gp160 is required for the activation of
625 human immunodeficiency virus. *Cell* 53:55–67.

626 19. Wyatt R, Sodroski J. 1998. The HIV-1 Envelope Glycoproteins: Fusogens, Antigens,
627 and Immunogens. *Science* 280:1884–1888.

628 20. Allan JS, Coligan JE, Barin F, McLane MF, Sodroski JG, Rosen CA, Haseltine WA,
629 Lee TH, Essex M. 1985. Major Glycoprotein Antigens That Induce Antibodies in AIDS
630 Patients Are Encoded by HTLV-III. *Science* 228:1091–1094.

631 21. Robey WG, Safai B, Oroszlan S, Arthur LO, Gonda MA, Gallo RC, Fischinger PJ.
632 1985. Characterization of Envelope and Core Structural Gene Products of HTLV-III with
633 Sera from AIDS Patients. *Science* 228:593–595.

634 22. Lewis GK, Pazgier M, Evans DT, Ferrari G, Bournazos S, Parsons MS, Bernard NF,
635 Finzi A. 2017. Beyond Viral Neutralization. *AIDS Res Hum Retroviruses* 33:760–764.

636 23. Veillette M, Coutu M, Richard J, Batrville L-A, Dagher O, Bernard N, Tremblay C,
637 Kaufmann DE, Roger M, Finzi A. 2015. The HIV-1 gp120 CD4-Bound Conformation Is
638 Preferentially Targeted by Antibody-Dependent Cellular Cytotoxicity-Mediating
639 Antibodies in Sera from HIV-1-Infected Individuals. *J Virol* 89:545–551.

- 640 24. Veillette M, Désormeaux A, Medjahed H, Gharsallah N-E, Coutu M, Baalwa J, Guan
641 Y, Lewis G, Ferrari G, Hahn BH, Haynes BF, Robinson JE, Kaufmann DE, Bonsignori
642 M, Sodroski J, Finzi A. 2014. Interaction with cellular CD4 exposes HIV-1 envelope
643 epitopes targeted by antibody-dependent cell-mediated cytotoxicity. *J Virol* 88:2633
644 2644.
- 645 25. Richard J, Pacheco B, Gohain N, Veillette M, Ding S, Alsahafi N, Tolbert WD,
646 Prévost J, Chapleau J-P, Coutu M, Jia M, Brassard N, Park J, Courter JR, Melillo B,
647 Martin L, Tremblay C, Hahn BH, Kaufmann DE, Wu X, Smith AB, Sodroski J, Pazgier
648 M, Finzi A. 2016. Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose
649 Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins.
650 *Ebiomedicine* 12:208 218.
- 651 26. Richard J, Veillette M, Brassard N, Iyer SS, Roger M, Martin L, Pazgier M, Schoen
652 A, Freire E, Routy J-P, Smith AB, Park J, Jones DM, Courter JR, Melillo BN, Kaufmann
653 DE, Hahn BH, Permar SR, Haynes BF, Madani N, Sodroski JG, Finzi A. 2015. CD4
654 mimetics sensitize HIV-1-infected cells to ADCC. *Proc National Acad Sci* 112:E2687
655 E2694.
- 656 27. Prévost J, Richard J, Medjahed H, Alexander A, Jones J, Kappes JC, Ochsenbauer
657 C, Finzi A. 2018. Incomplete Downregulation of CD4 Expression Affects HIV-1 Env
658 Conformation and Antibody-Dependent Cellular Cytotoxicity Responses. *J Virol*
659 92:e00484-18.
- 660 28. Prévost J, Richard J, Ding S, Pacheco B, Charlebois R, Hahn BH, Kaufmann DE,
661 Finzi A. 2017. Envelope glycoproteins sampling states 2/3 are susceptible to ADCC by
662 sera from HIV-1-infected individuals. *Virology* 515:38 45.
- 663 29. Rajashekar JK, Richard J, Beloor J, Prévost J, Anand SP, Beaudoin-Bussi res G,
664 Shan L, Herndler-Brandstetter D, Gendron-Lepage G, Medjahed H, Bourassa C,
665 Gaudette F, Ullah I, Symmes K, Peric A, Lindemuth E, Bibollet-Ruche F, Park J, Chen
666 H-C, Kaufmann DE, Hahn BH, Sodroski J, Pazgier M, Flavell RA, Smith AB, Finzi A,
667 Kumar P. 2021. Modulating HIV-1 envelope glycoprotein conformation to decrease the
668 HIV-1 reservoir. *Cell Host Microbe* 29:904-916.e6.
- 669 30. Marchitto L, Richard J, Prévost J, Tauzin A, Yang D, Chiu T-J, Chen H-C, D    -
670 Salinas MA, Nayrac M, Benlarbi M, Beaudoin-Bussi res G, Anand SP, Dionne K,
671 B    nger   , Chatterjee D, Medjahed H, Bourassa C, Tolbert WD, Hahn BH, Munro JB,
672 Pazgier M, Smith AB, Finzi A. 2024. The combination of three CD4-induced antibodies
673 targeting highly conserved Env regions with a small CD4-mimetic achieves potent
674 ADCC activity. *bioRxiv* 2024.06.07.597978.
- 675 31. Anand SP, Prévost J, Baril S, Richard J, Medjahed H, Chapleau J-P, Tolbert WD,
676 Kirk S, Smith AB, Wines BD, Kent SJ, Hogarth PM, Parsons MS, Pazgier M, Finzi A.
677 2019. Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and
678 Eliminate HIV-1-Infected Cells. *J Virol* 93.

679 32. Ding S, Tolbert WD, Zhu H, Lee D, Marchitto L, Higgins T, Zhao X, Nguyen D,
680 Sherburn R, Richard J, Gendron-Lepage G, Medjahed H, Mohammadi M, Abrams C,
681 Pazgier M, Smith AB, Finzi A. 2023. Piperidine CD4-Mimetic Compounds Expose
682 Vulnerable Env Epitopes Sensitizing HIV-1-Infected Cells to ADCC. *Viruses* 15:1185.

683 33. Richard J, Nguyen DN, Tolbert WD, Gasser R, Ding S, Vézina D, Gong SY, Prévost
684 J, Gendron-Lepage G, Medjahed H, Gottumukkala S, Finzi A, Pazgier M. 2021. Across
685 Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and
686 Mediate Fc-Mediated Effector Killing of Infected Cells. *Mbio* 12:e01405-21.

687 34. Nikić I, Kang JH, Girona GE, Aramburu IV, Lemke EA. 2015. Labeling proteins on
688 live mammalian cells using click chemistry. *Nat Protoc* 10:780 791.

689 35. Richard J, Prévost J, Alsahafi N, Ding S, Finzi A. 2018. Impact of HIV-1 Envelope
690 Conformation on ADCC Responses. *Trends Microbiol* 26:253–265.

691 36. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, Delaporte E,
692 Peeters M, Derdeyn CA, Allen S, Hunter E, Saag MS, Hoxie JA, Hahn BH, Kwong PD,
693 Robinson JE, Shaw GM. 2005. Antigenic conservation and immunogenicity of the HIV
694 coreceptor binding site. *J Exp Med* 201:1407–1419.

695 37. Mukherjee S, Dowd KA, Manhart CJ, Ledgerwood JE, Durbin AP, Whitehead SS,
696 Pierson TC. 2014. Mechanism and Significance of Cell Type-Dependent Neutralization
697 of Flaviviruses. *J Virol* 88:7210–7220.

698 38. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and
699 CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human
700 Immunodeficiency Virus Type 1. *J Virol* 72:2855–2864.

701 39. Jain A, Govindan R, Berkman AR, Luban J, Díaz-Salinas MA, Durham ND, Munro
702 JB. 2023. Regulation of Ebola GP conformation and membrane binding by the chemical
703 environment of the late endosome. *PLOS Pathog* 19:e1011848.

704 40. Díaz-Salinas MA, Li Q, Ejemel M, Yurkovetskiy L, Luban J, Shen K, Wang Y, Munro
705 JB. 2022. Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike.
706 *Elife* 11:e75433.

707 41. Díaz-Salinas MA, Jain A, Durham ND, Munro JB. 2024. Single-molecule imaging
708 reveals allosteric stimulation of SARS-CoV-2 spike receptor binding domain by host
709 sialic acid. *Sci Adv* 10:eadk4920.

710 42. Das DK, Govindan R, Nikić-Spiegel I, Krammer F, Lemke EA, Munro JB. 2018.
711 Direct Visualization of the Conformational Dynamics of Single Influenza Hemagglutinin
712 Trimers. *Cell* 174:926 937.e12.

713 43. Das DK, Bulow U, Diehl WE, Durham ND, Senjobe F, Chandran K, Luban J, Munro
714 JB. 2020. Conformational changes in the Ebola virus membrane fusion machine
715 induced by pH, Ca²⁺, and receptor binding. Plos Biol 18:e3000626.

716 44. Blakemore RJ, Burnett C, Swanson C, Kharytonchyk S, Telesnitsky A, Munro JB.
717 2021. Stability and conformation of the dimeric HIV-1 genomic RNA 5'UTR. Biophys J
718 <https://doi.org/10.1016/j.bpj.2021.09.017>.

719 45. Juette MF, Terry DS, Wasserman MR, Altman RB, Zhou Z, Zhao H, Blanchard SC.
720 2016. Single-molecule imaging of non-equilibrium molecular ensembles on the
721 millisecond timescale. Nat Methods 13:341–344.

722 46. Qin F, Auerbach A, Sachs F. 2000. A Direct Optimization Approach to Hidden
723 Markov Modeling for Single Channel Kinetics. Biophys J 79:1915–1927.

724

725




Fig 1. HIV-1_{CRF01_AE} strain 703357 is more susceptible to ADCC than HIV-1_{JR-FL}. (A) Binding of plasma from PLWH to primary CD4+ T cells infected with the indicated HIV-1 strains was evaluated. Five independent experiments (n=5) were performed with each one of the ten plasma samples plotted as individual dots. Means are shown as horizontal bars. (B) ADCC responses to the indicated viral strains. Data are plotted as in (A). In this case, the number of independent experiments were 5 and 4 for HIV-1_{CRF01_AE} and HIV-1_{JR-FL}, respectively. Statistical significance was determined through an unpaired two-tailed Mann-Whitney *t*-test and *p*-values < 0.05 were considered statistically significant.




Fig 2. Engineering HIV-1_{CRF01_AE} Env for site-specific fluorescent labeling. (A) Schematic of the smFRET imaging assay. Pseudovirions with HIV-1_{CRF01_AE} Env (strain 92TH023) containing a single labeled gp120 domain were immobilized on quartz slides and imaged using TIRF microscopy. (B) Sequence alignments indicating sites of A4 peptide insertion into the V1 loop and TCO* substitution in the V4 loop for fluorophore attachment. (C) Qualitative detection of the indicated proteins from purified pseudovirions with HIV-1_{CRF01_AE} Env through immunoblots. Lane 1, mock-produced virus; lane 2, ΔEnv virions; lane 3, wild-type Env pseudotyped virions; lane 4, Env V1-A4/V4-TAG (tagged) pseudotyped virions produced in the absence of the TCO* amino acid; lane 5, tagged Env pseudovirions produced in the presence of the TCO* amino acid. (D) Infectivity of lentiviruses with either wild-type HIV-1_{CRF01_AE} Env (wt), V1-A4/V4-TAG Env (tagged), or bald particles was evaluated in TZM-bl cells. Infectivity values are expressed as the percentage of wild-type Env and normalized to the expression level of gp120 and p24. Each point indicates the arithmetic mean of three technical replicates. Bars represent the average of three independent experiments per condition. Error bars reflect the standard error. The statistical significance was evaluated through parametric *t*-tests. *p*-values are indicated and those <0.05 were considered statistically significant.




Fig 3. Conformational equilibrium of HIV-1_{CRF01_AE} Env. (A) FRET histograms from unbound HIV-1_{JR-FL} Env trimers, or Env pre-incubated with sCD4^{D1D2}, or sCD4^{D1D2} and 17b, as indicated. FRET histograms are presented as the mean $\pm$ standard error determined from three technical replicates and the total number of smFRET traces used in the HMM analysis is shown (N). Overlaid on the histograms are four Gaussian distributions shown in grey and centered at 0.22 (State 1), 0.45 (State 3), 0.70 (State 2), and 0.85 (State 2A) FRET as determined through HMM analysis. The sum of the four Gaussians is shown in red. (B) The same data acquired for HIV-1_{CRF01_AE} Env trimers. Corresponding numeric FRET state occupancies are shown in **Table 2**.

Table 1. Characteristics of the cohort of people living with HIV, related to Fig. 1.

Donors	Sex	Age (years)	Days since infection	Days between inf. and ART	Viral load (copies/mL)	CD4 count (cells/mm ³)
P5	M	33	936	192	50	1149
P8	M	42	999	N/A	28666	260
P10	M	58	961	204	50	170
P13	M	28	1194	N/A	809600	200
P16	F	36	1576	833	50	570
P25	M	33	1173	N/A	35922	421
P30	M	40	1143	N/A	34759	691
P43	M	34	856	1098	29234	410
P44	M	34	1018	534	40	600
P46	M	56	1005	986	40	780

Table 2. FRET-state occupancies for HIV-1 Env in the presence and absence of sCD4^{D1D2} and 17b.

Strain/variant Env	Experimental condition	FRET state occupancies (%) ^a			
		State 1	State 3	State 2	State 2A
JR-FL	Unbound	68±2	32±2	0±2	0±1
	+ sCD4 ^{D1D2}	35±2	44±2	18±2	3±1
	+ sCD4 ^{D1D2} /17b	31±3	46±3	15±2	8±2
CRF01_AE	Unbound	42±2	27±2	19±2	12±1
	+ sCD4 ^{D1D2}	39±2	33±2	18±2	10±2
	+ sCD4 ^{D1D2} /17b	29±3	34±2	21±2	17±2

^aData are presented as mean ± standard error determined from the total population of traces analyzed.